Digestive diseases and sciences · 2026
Candida Enteritis Diagnoses in the United States: Prevalence and Clinical Insights from a Large Commercial Insurance Database.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Benedict Kaitlin, Gold Jeremy A W, Pimentel Mark
Аннотация
BACKGROUND: Candida overgrowth in the small intestine can cause non-specific gastrointestinal symptoms mimicking those of other conditions, making diagnosis challenging.
AIMS: To describe the characteristics of patients with Candida-related intestinal illness in a large US commercial health insurance claims dataset.
METHODS: We used the Merative™ MarketScan® Commercial/Medicare Database to identify patients who received Candida enteritis diagnosis codes.
RESULTS: We identified 3,710 patients. Rates were higher among women (20.3/100,000), patients ages 35-44 (19.3/100,000) and in the West (28.1/100,000). Fatigue (44%) and abdominal pain (26%) were common symptoms. Few patients (6%) received an esophagogastroduodenoscopy, the preferred diagnostic method, and 38% received systemic antifungal therapy.
CONCLUSIONS: Increased healthcare provider awareness about proper diagnosis and treatment of intestinal Candida overgrowth could be beneficial.
AIMS: To describe the characteristics of patients with Candida-related intestinal illness in a large US commercial health insurance claims dataset.
METHODS: We used the Merative™ MarketScan® Commercial/Medicare Database to identify patients who received Candida enteritis diagnosis codes.
RESULTS: We identified 3,710 patients. Rates were higher among women (20.3/100,000), patients ages 35-44 (19.3/100,000) and in the West (28.1/100,000). Fatigue (44%) and abdominal pain (26%) were common symptoms. Few patients (6%) received an esophagogastroduodenoscopy, the preferred diagnostic method, and 38% received systemic antifungal therapy.
CONCLUSIONS: Increased healthcare provider awareness about proper diagnosis and treatment of intestinal Candida overgrowth could be beneficial.